GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trevi Therapeutics Inc (NAS:TRVI) » Definitions » Quick Ratio

Trevi Therapeutics (Trevi Therapeutics) Quick Ratio : 15.03 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Trevi Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Trevi Therapeutics's quick ratio for the quarter that ended in Dec. 2023 was 15.03.

Trevi Therapeutics has a quick ratio of 15.03. It generally indicates good short-term financial strength.

The historical rank and industry rank for Trevi Therapeutics's Quick Ratio or its related term are showing as below:

TRVI' s Quick Ratio Range Over the Past 10 Years
Min: 2.98   Med: 8.33   Max: 15.03
Current: 15.03

During the past 7 years, Trevi Therapeutics's highest Quick Ratio was 15.03. The lowest was 2.98. And the median was 8.33.

TRVI's Quick Ratio is ranked better than
89.56% of 1551 companies
in the Biotechnology industry
Industry Median: 3.51 vs TRVI: 15.03

Trevi Therapeutics Quick Ratio Historical Data

The historical data trend for Trevi Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trevi Therapeutics Quick Ratio Chart

Trevi Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial 11.45 8.33 2.98 9.15 15.03

Trevi Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.15 8.65 21.06 18.16 15.03

Competitive Comparison of Trevi Therapeutics's Quick Ratio

For the Biotechnology subindustry, Trevi Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trevi Therapeutics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Trevi Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Trevi Therapeutics's Quick Ratio falls into.



Trevi Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Trevi Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(87.547-0)/5.824
=15.03

Trevi Therapeutics's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(87.547-0)/5.824
=15.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Trevi Therapeutics  (NAS:TRVI) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Trevi Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Trevi Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Trevi Therapeutics (Trevi Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
195 Church Street, 16th Floor, New Haven, CT, USA, 06510
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Executives
Lisa Delfini officer: Chief Financial Officer C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FL. 14, NEW HAVEN CT 06510
Farrell Simon officer: Chief Commercial Officer C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FLOOR 14, NEW HAVEN CT 06510
David J Clark officer: Chief Medical Officer 131 HARTWELL AVE, LEXINGTON MA 02421
Tpg Gp A, Llc 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Scott D Sandell 10 percent owner
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker director 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Forest Baskett 10 percent owner
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Ali Behbahani 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Jon Winkelried 10 percent owner C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Christopher Galletta officer: See Remarks 195 CHURCH STREET, FLOOR 14,, NEW HAVEN CT 06510